Bláha V, Zadák Z, Solichová D, Brátová M, Havel E
Department of Metabolic Care and Gerontology, Charles University, Faculty of Medicine and Teaching Hospital, Hradec Králové.
Acta Medica (Hradec Kralove). 1998;41(2):87-90.
Metabolic studies support the findings that antioxidants inhibit atherosclerosis. Treatment with vitamin E reduced both the susceptibility of low density lipoprotein cholesterol (LDL-C) to in vivo lipid peroxidation and atherosclerosis and smooth muscle proliferation. Thus the aim of present study was to examine metabolic consequences of reduced plasma LDL-C during hypolipidemic therapy and the distribution of antioxidant vitamin E. A group of 10 patients (4 men, 6 women, age 35-65y) with familial hypercholesterolaemia was treated using pravastatin (Lipostat Bristol Myers Squibb, 40 mg daily at 6:00 PM). Blood samples were examined before treatment, after 4 and 8 weeks of therapy. After ultracentrifugation, samples were analyzed for lipoprotein fractions and the content of vitamin E and cholesterol. Pravastatin reduced both total cholesterol (9.85 +/- 0.74 vs. 6.81 +/- 0.51 mmol/1; p < 0.01), LDL-C (6.42 +/- 0.45 vs. 4.51 +/- 0.45 mmol/l; p < 0.01), light LDL1-C (4.56 +/- 0.50 vs. 3.11 +/- 0.34 mmol/l; p < 0.05) and dense LDL2-C (1.86 +/- 0.27 vs. 1.42 +/- 0.17 mmol/l; ns). Serum vitamin E was reduced during hypolipidemic therapy in the fraction of total, LDL1, LDL2, and VLDL-cholesterol. However, the ratio of serum vitamin E/total serum cholesterol (4.57 +/- 0.32 vs. 5.12 +/- 0.37 mmol/l/mmol/l; p < 0.05) and ratio of LDL2-C vitamin E/LDL2-C (3.92 +/- 0.07 vs. 4.64 +/- 0.37 mmol/l/mmol/l; p = 0.08) increased in comparison to pre-treatment values. We conclude that pravastatin therapy may possess anti-atherogenic properties which involve not only its hypocholesterolemic effect, but also its favorable effects on the distribution of LDL subclasses and the content of antioxidant vitamin E in atherogenic lipoproteins.
代谢研究支持抗氧化剂可抑制动脉粥样硬化这一发现。维生素E治疗可降低低密度脂蛋白胆固醇（LDL-C）在体内的脂质过氧化敏感性、动脉粥样硬化以及平滑肌增殖。因此，本研究的目的是探讨降脂治疗期间血浆LDL-C降低的代谢后果以及抗氧化剂维生素E的分布情况。一组10例家族性高胆固醇血症患者（4例男性，6例女性，年龄35 - 65岁）使用普伐他汀（立普妥，百时美施贵宝公司生产，每日下午6点服用40毫克）进行治疗。在治疗前、治疗4周和8周后采集血样。超速离心后，对样本进行脂蛋白组分以及维生素E和胆固醇含量分析。普伐他汀降低了总胆固醇（9.85±0.74对6.81±0.51毫摩尔/升；p<0.01）、LDL-C（6.42±0.45对4.51±0.45毫摩尔/升；p<0.01）、轻LDL1-C（4.56±0.50对3.11±0.34毫摩尔/升；p<0.05）和致密LDL2-C（1.86±0.27对1.42±0.17毫摩尔/升；无显著性差异）。在降脂治疗期间，血清维生素E在总胆固醇、LDL1、LDL2和极低密度脂蛋白胆固醇组分中均降低。然而，血清维生素E/总血清胆固醇比值（4.57±0.32对5.12±0.37毫摩尔/升/毫摩尔/升；p<0.05）以及LDL2-C维生素E/LDL2-C比值（3.92±0.07对4.64±0.37毫摩尔/升/毫摩尔/升；p = 0.08）相较于治疗前值升高。我们得出结论，普伐他汀治疗可能具有抗动脉粥样硬化特性，这不仅涉及其降胆固醇作用，还涉及其对LDL亚类分布以及致动脉粥样硬化脂蛋白中抗氧化剂维生素E含量的有利影响。
